FDA 510(k) Clearance Trends 1995-2026: Volume Stable as Traditional Submissions Take Share

Executive Summary

The FDA's 510(k) premarket-notification program is the dominant route to the US medical device market — roughly 3,200 devices are cleared through it each year, far more than reach market through PMA or De Novo. But the program is not static. Our analysis of 175,149 clearance records spanning 1995 through 2026 finds a program whose total volume has stabilized while its internal composition has shifted meaningfully:

• Annual clearance volume has been stable for nearly two decades, settling at roughly 3,000-3,350 clearances per year after 2007, down from mid-1990s peaks above 5,400 — consistent with FDA's own reporting of ~3,100-3,300 510(k) authorizations per fiscal year.
• The clearance-type mix has shifted decisively toward Traditional 510(k)s, which grew from 73% of clearances in 2005-2009 to 83% in 2025-2026, while Special 510(k)s fell from 23% to 15% and Abbreviated 510(k)s collapsed from 4% to near 1%.
• A small group of large manufacturers dominates the applicant base: Abbott (883 clearances), Siemens (779), C.R. Bard (645), BD (632), and Smith & Nephew (529) lead the all-time applicant ranking.
• The published record skews heavily toward successful clearances: in recent years, more than 98% of 510(k) records with a recorded decision carry a "Substantially Equivalent" determination, a function of the database's structure and the relative rarity of published non-SE outcomes.

For regulatory affairs teams, the composition shift is the most actionable finding: the practical center of gravity of the 510(k) program is now the Traditional submission, and pathway-selection strategy must reflect that Special and Abbreviated routes have narrowed rather than broadened over the last two decades.

Why the 510(k) Mix Matters

The 510(k) program is not a single pathway but a family of three. A Traditional 510(k) is the default — used for a first-of-kind device or any change that does not qualify for a faster route, it requires a full demonstration of substantial equivalence to a predicate. A Special 510(k), created in 1998, is a streamlined route for modifications to a manufacturer's own already-cleared device, where the firm's design-control procedures are expected to produce the data establishing equivalence; FDA targets a 30-day review. An Abbreviated 510(k), also from 1998, lets a manufacturer rely on FDA guidance documents, special controls, or voluntary consensus standards rather than a head-to-head predicate comparison.

Which route a submission takes has real consequences for timeline, cost, and the type of evidence required. So a decade-long shift in the share of clearances going to each route is not a technicality — it reflects how the FDA has come to administer the program, how industry has come to use it, and where the practical bottlenecks now sit. Our data quantifies that shift directly.

Data Source and Method

• Analysis sample: 175,149 records from the FDA 510(k) clearance database (the full premarket-notification extract), covering clearances dated 1995 through 2026.
• Method: All counts were computed by MedDeviceGuide from the public FDA 510(k) extract. Records were grouped by calendar year of the FDA decision date and by the FDA-recorded clearance type (Traditional, Special, Abbreviated, Direct, Dual Track, Post-NSE). Applicant names were consolidated across corporate variants for the top-applicant ranking (for example, multiple Becton Dickinson and BD entities under BD; Bard entities under C.R. Bard). Period comparisons use five-year windows (and a partial 2025-2026 window for the most recent activity).

Annual Clearance Volume: A Post-2007 Plateau

The 510(k) program processed far more clearances per year in the mid-1990s than it does today, then settled into a stable band:

The decline from the 1995 peak reflects the maturation of the device industry and the consolidation of predicate families, not a contraction in device availability. The post-2007 plateau — roughly 3,000-3,350 clearances per year — is remarkably consistent and matches FDA's own fiscal-year reporting (3,229 in FY2022, 3,326 in FY2023, 3,107 in FY2024, and 3,238 in FY2025, per industry analyses of FDA data). For planning purposes, regulatory affairs teams can treat ~3,200 clearances per year as the durable throughput of the program.

The Headline Shift: Traditional's Rising Share

The clearest structural change in the 510(k) program over two decades is the migration of clearance volume into Traditional submissions and out of Special and Abbreviated submissions:

Two trends stand out. First, Special 510(k) share fell from 23% to 15% over two decades. The Special route is intended for well-defined modifications to a manufacturer's own predicate where design-control outputs are reviewable in summary form; as FDA has refined its 2019 Special 510(k) guidance and tightened the circumstances under which it will accept (rather than convert) a Special submission, a larger share of modifications have been routed back into Traditional review. Second, the Abbreviated 510(k) has all but disappeared, from 4% of clearances down to roughly 1%. The Abbreviated route's reliance on guidance documents and consensus standards has been largely superseded by the Safety and Performance-Based Pathway (the "substantial-equivalence via performance criteria" route finalized in 2019) and by direct predicate comparison, leaving Abbreviated as a rarely used option.

The net effect is that the Traditional 510(k) — the most evidence-intensive, predicate-comparison-driven route — now carries 83% of the program's volume, up from 73%. This is the practical environment in which regulatory teams now operate: the streamlined routes that were once expected to offload review burden have narrowed, and the full Traditional submission is the center of gravity.

The Decision Record: A Database That Skews Toward Clearance

The 510(k) database records a decision description for each submission, dominated by "Substantially Equivalent" determinations. In the most recent complete years:

More than 98% of records with a recorded decision in recent years carry a Substantially Equivalent determination. This is partly a real signal — most 510(k) submissions that reach a decision are cleared — and partly an artifact of the database's structure: submissions that are withdrawn or that receive a Not Substantially Equivalent (NSE) determination are less consistently represented in the public clearance extract, which is oriented around successful authorizations. The clearance-rate figure should therefore be read as a characteristic of the published record rather than as a precise estimate of the probability that any given submission is cleared. The MDUFA performance framework, by contrast, explicitly tracks withdrawal and NSE rates as a negotiated performance metric — a reminder that the operational reality includes outcomes the public database under-represents.

Who Clears the Most: The Applicant Concentration

The all-time applicant ranking reflects the same large-manufacturer concentration seen across the device market:

These firms clear the most 510(k)s because they hold the most predicate families and run the most active product-iteration cycles — the same firms that recur in the recall and PMA records. For a regulatory team benchmarking submission strategy, the practical observation is that the 510(k) applicant base is concentrated at the top and long-tailed below: a small group of incumbents generates a large share of annual volume, while the remaining ~3,200-per-year throughput is distributed across thousands of smaller applicants.

The Operating Context: Timelines, eSTAR, and MDUFA Reauthorization

The composition data should be read alongside the program's operating environment, where several 2023-2026 developments affect how a Traditional 510(k) moves through review:

• Review timelines. Under MDUFA V, the negotiated total time-to-decision goal for 510(k)s stepped down from 128 calendar days (FY2023) to 124 (FY2024) to 112 days (FY2025-2027). Industry tracking for 2025 reports actual average total review times of roughly 140-175 days, with 70-80% of submissions exceeding the 90-day FDA portion of the target — reflecting, in part, FDA information-request and refusal-to-accept cycles.
• eSTAR mandate. The electronic Submission Template And Resource (eSTAR) became mandatory for 510(k) submissions in October 2023 and for De Novo submissions in October 2025, standardizing the front end of submissions and reducing administrative incomplete-file rates.
• Third-party review. A November 2024 FDA final guidance updated the 510(k) Third-Party Review Program, clarifying accredited-reviewer responsibilities and reducing redundant FDA re-review for eligible device types.
• CDRH capacity. CDRH employs roughly 2,260 staff and processed more than 20,700 submissions of all types in 2024, but sustained staffing reductions in early 2025 have created operational pressure that industry observers expect to extend review timelines.
• MDUFA VI. The current fee-and-performance authorization (MDUFA V) expires September 30, 2027, and the FDA began the MDUFA VI reauthorization process with an August 2025 public meeting. The next authorization will set the timeline and review goals that govern 510(k) review for FY2028-2032.

What This Means for Regulatory Affairs Teams

1. Plan around Traditional review as the default. With Special and Abbreviated routes now carrying only ~16% of volume combined, regulatory teams should assume a full Traditional 510(k) evidence package for most modifications and treat Special-pathway eligibility as an exception to be validated against the 2019 guidance, not an assumption.
2. Budget for timeline, not just fee. The user-fee schedule is only one input. With average total review times running well above the negotiated FDA-portion goal, build project timelines around a 140-180-day total cycle (including FDA information requests) and front-load eSTAR completeness to avoid RTA and AI cycles.
3. Use the composition shift in pathway strategy. The decline of Abbreviated and the rise of the Safety and Performance-Based Pathway means that for device types with established performance criteria, a performance-based comparison may now be a more predictable route than the legacy Abbreviated approach.
4. Track the MDUFA VI outcome. The FY2028-2032 reauthorization will reset review-time goals and fees. Teams with multi-year pipelines should model the negotiated goals as they firm up through 2026-2027, since they directly affect submission sequencing and resourcing.

For the device industry, the two-decade stabilization of 510(k) volume combined with the steady migration into Traditional review tells a consistent story: the program's throughput has found its level, and the pathways within it have consolidated around the most evidence-intensive route. Strategy that assumes a faster, lighter-touch 510(k) environment is working from a picture that is now nearly two decades out of date.

Data sources: FDA 510(k) premarket-notification clearance database; analysis by MedDeviceGuide, run date 2026-06-16. Annual volume and clearance-type shares are computed from FDA decision dates and recorded clearance types. Applicant names were consolidated across corporate and legal-entity variants. Timeline, eSTAR, and MDUFA context is drawn from FDA guidance and MDUFA performance-goal documents cited above. This article is educational and is not regulatory advice for a specific product or submission.